Iteos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Iteos Therapeutics Inc ITOS.OQ reported a quarterly adjusted loss of $1.43​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of five analysts for the quarter was for a loss of $1.01 per share. Wall Street expected results to range from $-1.56 to -82 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Iteos Therapeutics Inc's reported EPS for the quarter was a loss of $1.81​.

• The company reported a quarterly loss of $78.73 million.

• Iteos Therapeutics Inc shares had risen by 1.4% this quarter and gained 31.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 10.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Iteos Therapeutics Inc is $10.10, about 0.1% below its last closing price of $10.11

This summary was machine generated from LSEG data August 7 at 07:28 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)